Weekly docetaxel and capecitabine in the treatment of advanced gastric cancer: A phase II study

被引：0
|
作者：
Orditura, M.
Aurilio, G.
Galizia, G.
Carlomagno, C.
Lieto, E.
Vecchione, L.
Martinelli, E.
De Placido, S.
Catalano, G.
Ciardiello, F.
De Vita, F.
机构：
[1] Univ Naples, Cattedra Oncol Med, Naples, Italy
[2] Univ Naples, Cattedra Chirurg Gen & Epatobiliare, Naples, Italy
[3] Univ Naples Federico II, Dipartimento Endocrinol & Oncol Mol & Clin, Naples, Italy
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：XI52 / XI52
页数：1
相关论文
共 50 条
  • [31] Phase I study of a treatment with Gemcitabine and docetaxel weekly in advanced pancreatic cancer
    Lueck, A
    Ridwelski, K
    Lippert, H
    ANNALS OF ONCOLOGY, 1998, 9 : 52 - 53
  • [32] A phase II study of weekly paclitaxel and doxifluridine (an intermediate metabolite of capecitabine) combination chemotherapy for advanced/recurrent gastric cancer
    Takeyoshi, I.
    Makita, F.
    Tanahashi, Y.
    Iwazaki, S.
    Nakamura, S.
    Ishikawa, H.
    Ogawa, T.
    Ohya, T.
    Kawate, S.
    Horiguchi, J.
    Morishita, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] Docetaxel and capecitabine for advanced gastric cancer: Phase II study investigating dose dependent efficacy in two patient cohorts
    Thuss-Patience, P. C.
    Kretzschmar, A.
    Dogan, Y.
    Rothmann, F.
    Blau, I.
    Schwaner, I.
    Lebedinzew, B.
    Grothoff, M.
    Doerken, B.
    Reichardt, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [34] A phase II study of capecitabine and weekly docetaxel combination chemotherapy in patients with metastatic breast cancer.
    Puglisi, F
    Scalone, S
    Minisini, AM
    Mansutti, M
    Crivellari, D
    Buonadonna, A
    Zanetti, M
    Ermacora, P
    Piga, A
    Veronesi, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 78S - 78S
  • [35] Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer
    Perez Manga, Gumersindo
    Khosravi Shahi, Parham
    Mendez Urena, Miguel
    Quiben Pereira, Rosa
    Palomero Plaza, Maria Isabel
    Izarzugaza Peron, Yann
    Gonzalez Del Val, Ricardo
    Belon Carrion, Joaquin
    Perez Canon, Esperanza
    Garcia Alfonso, Pilar
    BREAST CANCER, 2010, 17 (03) : 205 - 211
  • [36] Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer
    Gumersindo Pérez Manga
    Parham Khosravi Shahi
    Miguel Méndez Ureña
    Rosa Quiben Pereira
    María Isabel Palomero Plaza
    Yann Izarzugaza Peron
    Ricardo González Del Val
    Joaquín Belón Carrión
    Esperanza Pérez Cañón
    Pilar García Alfonso
    Breast Cancer, 2010, 17 : 205 - 211
  • [37] Phase II study of neoadjuvant treatment with docetaxel, doxorubicin and capecitabine (ATX) in locally advanced or inflammatory breast cancer
    Khosravi-Shahi, P.
    Mendez, M.
    Quiben, R.
    Palomero, I.
    Izarzugaza, Y.
    Belon, J.
    Garcia-Alfonso, P.
    Perez-Manga, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] Phase II Trial of Capecitabine and Weekly Docetaxel for Metastatic Castrate Resistant Prostate Cancer
    Vaishampayan, Ulka N.
    Marur, Shanthi
    Heilbrun, Lance K.
    Cher, Michael L.
    Dickow, Brenda
    Smith, Daryn W.
    Al Hasan, Samir A.
    Eliason, James
    JOURNAL OF UROLOGY, 2009, 182 (01): : 317 - 323
  • [39] A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced oesophageal cancer
    Hyun-Jeong Shim
    Dae-Eun Kim
    Jun-Eul Hwang
    Woo-Kyun Bae
    Taek-Keun Nam
    Kook-Joo Na
    Sang-Hee Cho
    Ik-Joo Chung
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 683 - 690
  • [40] A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced oesophageal cancer
    Shim, Hyun-Jeong
    Kim, Dae-Eun
    Hwang, Jun-Eul
    Bae, Woo-Kyun
    Nam, Taek-Keun
    Na, Kook-Joo
    Cho, Sang-Hee
    Chung, Ik-Joo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (05) : 683 - 690
12345